Stem cells in liver regeneration {#Sec1}
================================

Physiological homeostasis of the liver {#Sec2}
--------------------------------------

Under physiological conditions, as few as one out of 2000--3000 hepatocytes divide to maintain the physiological liver mass. Liver damage or loss of liver mass can however extensively stimulate the regenerative capacity until the tissue mass has been restored by the proliferation of mature parenchymal liver cells (Fausto et al. [@CR22]). Up to 75% of surgically removed liver mass can be regenerated within 1 week in rodents (Michalopoulos and DeFrances [@CR56]). Accelerated parenchymal regeneration after necrogenic or surgical loss of liver tissue principally originates from the extensive proliferation of mature parenchymal liver cells rather than from liver stem/progenitor cell proliferation. In a young adult rat or mouse, approximately 95% of hepatocytes replicate during the first 3 days after partial hepatectomy. This proportion drops to approximately 80% in senescent rats (Tsanev [@CR94]).

The newborn liver contains only diploid hepatocytes but polyploidisation and binuclearity occurs rapidly after birth. Fractionation of isolated adult rat hepatocytes based on cell density has yielded subpopulations with "small" mononucleated hepatocytes and "large" hepatocytes with higher ploidy. Hepatocytes with higher ploidy have been shown to reside predominantly in the perivenous areas and to contain more DNA and to exhibit greater maturity. The "smaller" mononucleated hepatocytes are located in the periportal areas, contain less DNA and exhibit greater growth factor responsiveness. The gradient of less complex cells with higher proliferation potential (in vitro) in periportal areas and more mature hepatocytes in perivenous areas has been interpreted as evidence for the existence of a physiological stem cell compartment (Sigal et al. [@CR81]). The "streaming liver hypothesis", which suggests that the liver lobule is organised in a similar way to the intestinal crypt by containing a stem cell pool arising form the periportal area has, however, been disproved by the observation that nearly all hepatocytes proliferate as a response to injury, regardless of location and ploidy.

Although mature hepatocytes and cholangiocytes represent the first and most important resource for tissue repair, experimental data support the hypothesis that the liver also contains or activates a stem cell compartment (Doyle and Ross [@CR19]; Lechner and Habener [@CR51]; Suzuki et al. [@CR85]).

Resident hepatic stem/progenitor cells {#Sec3}
--------------------------------------

Evidence for the existence and activation of a resident hepatic stem/progenitor cells (rHSPC) compartment has been provided from various murine animal models of "oval cell" proliferation (Alison et al. [@CR1]; Fausto [@CR20]; Thorgeirsson [@CR92]). The general principle underlying oval cell activation is based on a combination of liver injury and the inability of hepatocytes to proliferate in response to damage. For example, if a DNA-damaging agent is administered followed by partial hepatectomy, mitosis of hepatocytes is blocked, and oval-shaped cells emerge from the portal zone. These oval cells play a facultative role in liver regeneration, i.e. they contribute to tissue regeneration only in cases in which adult hepatocyte proliferation is inhibited or exhausted (Fausto and Campbell [@CR21]).

A cell compartment that has not as yet been defined gives rise to these rapid proliferating transient cells that subsequently differentiate into mature hepatocytes and bile duct cells. Anatomically, they arise from areas close to the terminal biliary duct (canals of Hering) of the liver, although additional locations have been described. To date, whether oval cells pre-exist in the tissue or develop from other adult cell types (i.e. bile duct cells) after an injury, is unknown. The restricted potential to differentiate into hepatocytes and cholangiocytes qualifies oval cells more as progenitor cells rather than true stem cells. Cell lines with "non-hepatocyte" phenotypes, which can function as lineage-generating precursors, have been derived from livers of rodents exposed to toxic chemicals or carcinogens and from normal liver with no histological evidence of stem/progenitor cell activation (Azuma et al. [@CR7]; Tsao et al. [@CR95]; Tsuchiya et al. [@CR96]).

The dissection and classification of cell populations on the basis of their molecular heterogeneity have become fundamental working tools in cell biology. For example, the differentiation state, lineage specificity or functional status of a given haematopoietic cell population can be precisely determined and communicated based on their antigenic and molecular properties (Mason et al. [@CR54]). In contrast to the haematopoietic cell lineage, the molecular characterisation of the stem cell compartments in solid organs still suffers from the lack of specific markers that unambiguously label all stem cells and only stem cells, enabling their prospective identification, cultivation and propagation. For a long time, this absence of tissue-specific stem cell markers has posed challenges to the identification and isolation of the "true" liver stem cell. A systematic understanding of the stem cell compartment and their respective cell lineages, however, is of fundamental importance for our understanding of physiological liver regeneration and liver tissue repair after injury and disease. A range of markers has been used to characterise the rHSPC compartment including a host of monoclonal antibodies against cytoskeletal proteins and unknown surface antigens. However, few appropriate cell surface markers that permit the fractionation of viable liver cell sub-populations by fluorescence-activated cell sorting exist. Some candidates have been suggested by a recent report on fetal liver epithelial cells (Nierhoff et al. [@CR62]). Another report on adult rat liver cells describes six surface markers unique to adult liver precursor cells, including CD133 (Yovchev et al. [@CR109]). Nevertheless, even the most basic parameters of resident liver stem/progenitor cells, such as their size, precise location within the liver and morphology, are not yet known in vary species.

For this reason, the stem/progenitor compartment of the liver is assumed to consist of cells with various phenotypes and multiple molecular markers. Most of the markers have been identified by immunohistochemistry from rodent models of oval cell activation. In multiple independent studies, these oval cells have been shown to share molecular markers with adult hepatocytes (albumin, cytokeratins 8 and 18), bile duct cells (cytokeratins 7 and 19, OV-6, A6), fetal hepatoblasts (AFP), and haematopoietic stem cells (Thy -1, Sca-1, c-kit). In a recently published mouse model with transgenic expression of the green fluorescence protein (GFP) under transcriptional control of nestin gene promoter and enhancer elements, Gleiberman and co-workers ([@CR26]) have identified, in the normal liver, GFP-marked cells at low frequencies with characteristic properties of oval cells, indicating a pre-formed stem/progenitor cell pool in the liver. Additional molecular markers have been identified by genome-wide analysis of mRNA expression in liver tissue and cells derived from rodent injury models with oval cell activation.

Such studies are beginning to elucidate the molecular markers and signalling pathways involved in stem cell/progenitor activation of the liver. One of these pathways involving stromal-derived factor 1 alpha (SDF-1α) has been shown to activate oval cells through SDF-1α/CXCR4 interactions (Hatch et al. [@CR32]). Other molecular pathways involving cytokines have been identified as mitogenic for oval cells. In the CDE diet model of oval cell activation in mice, the over-expression of tumour necrosis factor (TNF), interleukin-6 (IL-6), oncostatin M and others correlates with the rapid phase of oval cell expansion in the liver. The cytokine TWEAK (TNF-related weak inducer of apoptosis) may also specifically activate the rHSPC compartment in mouse liver through binding of the FN-14 receptor, which is expressed on the surface of biliary epithelial cells. Interestingly, unlike TNF or IL-6, TWEAK does not induce the proliferation of the mature hepatocytes and biliary duct epithelial cells (Jakubowski et al. [@CR39]).

Evidence from several laboratories suggests that hepatic stem/progenitor cells express the "side population" (SP)-phenotype similar to multipotent haematopoietic stem cells. The SP-phenotype of haematopoietic stem cells in mice and humans is largely determined by the expression of a protein known as the ABCG2 (BCRP1), viz. ATP-binding cassette transporter (Scharenberg et al. [@CR75]). The SP-cells in liver suspensions are phenotypically heterogeneous with subsets of these cells expressing diverse markers of haematopoietic cell lineages (Uchida et al. [@CR98]). In animal models of hepatic stem/progenitor cell (oval cell) activation, the mRNA of the ABCG2 transporter increases over time in liver tissue indicating an increasing proportion of hepatic stem cells within the non-parenchymal fraction of cells with the SP-phenotype (Shimano et al. [@CR80]). From the data available so far, we can conclude that cells characterised by the SP-phenotype as the common marker account for most of the stem cell activities in their respective organs.

Protocols for the isolation, culture and propagation of resident liver stem/progenitor cells have been established for several decades. Resulting cell lines have drawn attention, both for their therapeutic potential and for their usefulness in exploring the molecular events surrounding liver development and regeneration. Oval cell lines have mostly been derived from liver of rodents exposed to chemicals and carcinogens. Non-hepatocyte epithelial cell lines have also been propagated from normal livers without evidence for oval cell activation. Resulting cell lines have received the generic name "liver epithelial cell lines". As an example, postnatal mouse liver cells can now be enriched with clonogenic growth potential by using existing cell surface markers (Li et al. [@CR52]). The cells are isolated by single-cell cloning and express liver progenitor cell markers and some antigens shared by bone-marrow-derived haematopoietic stem cells, such as c-Kit and Thy-1. When cultured as aggregates in Matrigel, the mouse liver progenitor cells differentiate into hepatocytes upon treatment with epithelial growth factor (EGF) or differentiate into biliary lineage cells upon treatment with hepatocyte growth factor (HGF). In the presence of dimethylsulphoxide and Matrigel, the cells acquire predominantly bile-lineage phenotypes. Upon transplantation into CCl~4~-injured liver, engraftment into liver parenchyma and differentiation into hepatocytes have been demonstrated.

Most of the protocols to induce oval cells from murine liver tissue involve treatment of the animals with carcinogens and are thus not appropriate for the isolation of respective human cell populations. Alternatively, Parent and colleagues have established HepaRG cell lines with a dual differentiation potential from a liver associated with chronic hepatitis C infection (Cerec et al. [@CR13]; Parent et al. [@CR64]). One recent study has reported the successful isolation of a stem cell population from a normal adult human liver. Unlike most of the other studies on oval/progenitor cells, these isolated stem cells are closely related to mesenchymal stem cells and do not express haematopoietic markers (Herrera et al. [@CR34]). So far, none of these protocols to isolate human liver progenitor cells would fulfil the requirements for clinical application.

In the human liver, progenitor cell activation has been associated with a variety of liver diseases and the number of progenitor cells has been related to the severity of the disease (Roskams et al. [@CR72]). In parallel to our knowledge of these rodent models, inhibition of the replication of mature hepatocytes is also inhibited in human liver diseases. Recently, hepatocytes have been shown to become senescent, following telomere shortening, in the cirrhotic stage of a wide variety of chronic human liver diseases (Marshall et al. [@CR53]; Wiemann et al. [@CR104]). Probably, this hepatocyte replicative senescence is in part the result of ongoing proliferation during 20--30 years of chronic liver disease. Chronic inflammation and the presence of growth factors and DNA-damaging agents, such as reactive oxygen species and nitrogen species, also play a role. Several chronic human liver diseases display oval cell proliferation, particularly primary biliary cirrhosis (Bisgaard et al. [@CR9]; Tan et al. [@CR86]). Evidence is increasing that "progenitor cell" proliferation is associated with the evolution of hepatocarcinoma and cholangiocarcinoma (Alison and Lovell [@CR2]; Petersen [@CR65]). However, whether oval cells are simply a marker of carcinogenic disease states or whether oval cells are at particular risk of transformation still remains unclear.

Extrahepatic stem cells as a source for liver cells? {#Sec4}
----------------------------------------------------

In the last few years, many reports have suggested that extrahepatic stem cells participate in liver regeneration and may be useful for treating many diseases (Alison et al. [@CR3]; Herzog et al. [@CR35]; Lagasse et al. [@CR50]; Petersen et al. [@CR67]; Theise et al. [@CR90],[@CR91]). However, subsequent work by several independent groups has clearly shown that hepatocyte replacement levels after bone marrow transplantation are low (\<0.01%), unless the bone-marrow-derived hepatocytes have a selective growth advantage (Cantz et al. [@CR12]; Kanazawa and Verma [@CR45]; Wagers et al. [@CR100]). Furthermore, in most of the cases, fusion with host hepatocytes, rather than transdifferentiation of extrahepatic cells, has been described as the underlying principle (Alvarez-Dolado et al. [@CR4]; Quintana-Bustamante et al. [@CR69]; Vassilopoulos et al. [@CR99]; Wang et al. [@CR102]; Willenbring et al. [@CR105]). Apparently, extrahepatic cells are not directly involved in liver regeneration but may be a suitable tool to correct a metabolic defect by fusion-mediated additive gene transfer. This will be discussed at the end of the second section of this review.

(Stem) Cell-based therapies for liver disorders {#Sec5}
===============================================

Mature (adult) hepatocytes {#Sec6}
--------------------------

Despite their restricted proliferation capacity in vitro, adult hepatocytes show a high proliferation capacity in vivo. Experiments with serial murine hepatocyte transplantations in mice deficient in fumaryl-acetoacetate hydrolase (FAH^-^) have demonstrated more than 69 cell doublings or a 7.3×10^20^-fold expansion (Overturf et al. [@CR63]). About 30 years ago, the first animal experiments showed isolated hepatocytes suitable for the treatment of liver diseases. For example, the Gunn rat is a model for UDP-glucuronosyl transferase (UGT1A1) deficiency (Crigler-Najjar syndrome type I) leading to high serum bilirubin levels. After transplantation of primary adult hepatocytes into these animals, the bilirubin level is markedly reduced, although not normalised (Matas et al. [@CR55]). Many other animal models for human liver disorders have also been studied for the potential of hepatocyte transplantation, including metabolic disorders such as Wilson's disease (Long-Evans cinnamon rats; Yoshida et al. [@CR108]), tyrosinemia (FAH^-^ mice; Overturf et al. [@CR63]), hypercholesterolemia (Watanabe rabbit; Wiederkehr et al. [@CR103]), intrahepatic cholestasis mdr3^-/-^ mice (De Vree et al. [@CR16]), and ornithine transcarbamylase (OTC) deficiency (spf-ash mice; Michel et al. [@CR57]).

Meanwhile, a considerable number of patients treated for metabolic disorders has been reported. In 1998, a 10-year-old girl suffering from Crigler-Najjar syndrome type I was treated with an infusion of 7.5×10^9^ hepatocytes through the portal vein for partial correction of the metabolic defect. By 11 months after transplantation, the need for daily phototherapy had decreased from 10--12 h to 6--7 h and lowered the serum bilirubin from 450 μmol/l to 240 μmol/l (Fox et al. [@CR23]). Under immunosuppression with tacrolimus, no signs of rejection of the cells were observed. Despite the possibility of repeated transplantation, a conventional liver transplantation was successfully performed 2.5 years after the cell transplantation. Some other cases have been described in the last few years, including a newborn boy with OTC deficiency (Horslen et al. [@CR36]), a 4-year-old girl with a peroxisomal biogenesis defect (Refsum disease; Sokal et al. [@CR82]) and a 47-year-old woman with glycogen storage disease type 1a (Muraca et al. [@CR60]). A recent review of Anil Dhawan and colleagues summarises the outcome of 20 treated patients and ends with the conclusion that considerable progress has been made in developing the technique but that hepatocyte transplantation is limited by the available supply of liver tissue. Hepatocytes derived from stem cells might provide alternative sources of cells in the future (Dhawan et al. [@CR17]).

Few studies on liver cell therapy for the treatment of acute liver failure in humans have the intention to bridge the gap until patients until receive orthotopic liver transplantations (Bilir et al. [@CR8]; Schneider et al. [@CR76]; Strom et al. [@CR84]). The main challenges for this approach are the number of transplanted cells, the availability of freshly prepared cells or the quality of cryoconserved cells and the need for immunosuppression to prevent the rejection of the transplanted cells. The last-mentioned point may become more important than has been previously considered because liver failure itself gives a high risk for septic complications, which will be aggravated by immunosuppressive drugs.

Fetal hepatic progenitor cells {#Sec7}
------------------------------

Recent studies with transplantations of fetal liver cells show a higher proliferation capacity in the host liver than after treatment with adult hepatocytes. In rats, clusters of 500--1000 cells have been observed after fetal liver cell transplantation and partial hepatectomy for stimulation of liver regeneration. This equals an expansion of approximately nine- to ten-fold after 6 months and a repopulation efficacy of 6%--10%. If the rats have been pre-treated with retrorsine, which blocks endogenous hepatocyte proliferation capacity before transplantation, a repopulation of as high as 80% is achieved (Sandhu et al. [@CR74]). After transplantation of mouse fetal liver cells into 14-- to 20-day-old uPA-mice, which develop sub-acute liver failure caused by the expression of the uroplasminogen activator (uPA) under the control of the albumin promoter, donor-derived regeneration nodules were also detectable. They show a mature hepatic phenotype as established by gene expression profiling and a functional integration within in the first 4 weeks after transplantation (Cantz et al. [@CR11]). Thus, fetal liver cells may be suitable for overcoming the limitations in engraftment and to allow a functional correction of the disease phenotype, at least in disorders in which a low percentage of cells with a correct genotype are sufficient. Only a few studies have reported, by using human fetal liver cells in the treatment of acute liver failure, modest clinical improvement (Habibullah et al. [@CR29]). Nevertheless, ethical issues to be considered if fetuses from late abortions are necessary, and as for adult hepatocytes, the need for immunosuppressive regimens will cause additional problems.

Bone-marrow-derived cells {#Sec8}
-------------------------

Eight years ago, B. Petersen, M. Alison and N. Theise were among the first to describe the contribution of bone-marrow-derived cells to liver regeneration. They analysed sex-mismatched bone marrow and liver transplantations in rats (Petersen et al. [@CR67]), mice (Theise et al. [@CR90]) and humans (Alison et al. [@CR3]; Theise et al. [@CR91]) and were able to show Y-chromosome-positive hepatocytes as single cells or small clusters in the recipients.

Since the liver is the site for haematopoiesis at fetal stages, haematopoietic stem cells might have the capability to generate oval cell and parenchymal liver cells also in the adult organ. In adults, the haematopoietic stem cells reside in the bone marrow and have the ability to reconstitute all haematopoietic cell lineages and to rescue lethally irradiated animals from bone marrow failure. Some of the markers of haematopoietic stem cells, for example, c-kit, stem cell factor (SCF) and Thy-1, are also expressed by the putative resident hepatic stem/progenitor cells, which occur in the liver in response to several modes of injury as described above (Fujio et al. [@CR24]; Petersen et al. [@CR66], [@CR68]). The first reports about the formation of hepatocytes from haematopoietic stem cells in vivo came up in the late nineties and suggested a wider plasticity of HSC than previously known.

The most convincing study was reported by E. Lagasse, who demonstrated that haematopoietic stem cells (c-kit^+^, lin^-^, Sca^+^ and thy-1^low^) give rise to functional hepatocytes (Lagasse et al. [@CR50]). The presence of large donor-derived regeneration nodules can rescue mice from a lethal disease of hereditary tyrosinemia, and functional assays have been performed to identify and characterise the differentiated cells. However,this particular model provides strong selection pressure on FAH-positive transplanted cells regulated by repeated withdrawal of the compound NTBC (nitro-trifluoro-methylbenzol-cyclohexanedione). Two lessons were to be learned from his experiments. First, a high selection pressure seemed to be necessary for repopulation of a significant part of the liver with bone-marrow-derived cells. Second, only a few cells gave the origin of the small numbered but big sized regeneration nodules. Hence, two years later, a comment of C. Mitchell and N. Fausto summarises the role of bone-marrow-cell-derived liver regeneration as: "rare, but promising" (Mitchell and Fausto [@CR58]). So far, bone-marrow-derived cells have been used only in non-controlled, non-randomised phase-I clinical trials with a few patients suffering from chronic liver diseases (Gordon et al. [@CR27]; Terai et al. [@CR88]). The authors of these studies report an improvement of liver function in a subset of patients, but these findings should be interpreted carefully, as no control group was investigated. Autologous CD133-positive bone marrow cells have been used to improve the expansion of the residual liver lobe after portal vein embolisation of tumor-bearing liver segments (am Esch et al. [@CR5]; Furst et al. [@CR25]). Compared with a control group, the increase in the liver volume is significantly higher in the CD133-treated group but whether this effect is attributable to cell engraftment and transdifferentiation, to regenerative factors secreted by the transplanted cells or to the method of cell preparation remains unclear.

Therefore, we speculate that bone marrow transplantation without expansion of the resulting donor hepatocytes might not be therapeutically effective and that sophisticated methods have to be applied to increase the number of stem-cell-derived hepatocytes in the recipient liver. Three main determinants could influence the role of stem cells in liver repopulation: (1) the time course, severity and type of liver tissue injury, (2) the expression of homing factors for stem cells in the recipient liver and (3) a sufficient number of circulating haematopoietic stem cells at the time of tissue regeneration. Cantz et al. ([@CR12]) have tested two of the three variables by application of the liver toxin carbon tetrachloride (CCl~4~) to induce liver tissue injury and by mobilising the bone marrow stem cells into the peripheral blood by granulocyte colony-stimulating factor (G-CSF). The authors have found no evidence of an effect of CCl~4~ and/or stem cell mobilisation regimens on the usual low transdifferentiation rate of bone marrow cells into hepatocytes (Cantz et al. [@CR12]). In another study, Kanazawa and Verma ([@CR45]) have addressed the effect of acute and chronic liver injury on bone-marrow-derived hepatocyte formation. They have used three different models of liver injury: (1) CCl~4~ application to induce toxic liver damage, (2) the albumin-urokinase transgenic mouse model with sub-acute intrinsic liver failure and (3) the hepatitis B transgenic mouse representing a chronic liver disease model. Bone-marrow-derived cells from GFP- or β-galactosidase transgenic mice were transplanted into irradiated sex-mismatched mice. Even 47 weeks after transplantation, only a low number of transgene-marked bone-marrow-derived hepatocytes was detected in any of the recipient mice (Kanazawa and Verma [@CR45]).

In the meantime, several groups have made progress in elucidating the mechanism of the observed stem cell plasticity, which was first considered to be transdifferentiation. Several studies have clearly shown that the correction of the FAH^-/-^ phenotype is attributable to the fusion of bone-marrow-derived cells with host hepatocytes (Alvarez-Dolado et al. [@CR4]; Vassilopoulos et al. [@CR99]; Wang et al. [@CR102]). In the most detailed study (Willenbring et al. [@CR105]), several controversial points have been addressed: (1) no fusion of mature hepatocytes has been observed, which strongly disproves a transdifferentiation-followed-by-fusion theory, (2) bone marrow reconstitution is not necessary to induce fusion of host hepatocytes and granulocyte-macrophage progenitors, (3) even after intrasplenic transplantation of in vitro differentiated mature macrophages, fusion between donor and host cells is observed. The authors conclude that the administration of fusogenic macrophages to the damaged organ represents a targeted therapeutic strategy (Willenbring et al. [@CR105]). Quintana-Bustamante and co-workers ([@CR69]) have applied CCl~4~ over 3 months followed by injection of pegylated G-CSF for up to 3 weeks in mice that had been irradiated and reconstituted with GFP-marked bone marrow. The authors have demonstrated that the observed bone-marrow-derived hepatocytes do not originate from the differentiation of haematopoietic stem cells but are generated by fusion. The number of bone-marrow-derived hepatocytes is much lower than previously reported and only marginally increased by chronic liver injury and mobilisation of bone marrow stem cells (Quintana-Bustamante et al. [@CR69]).

Thorgeirsson and Grisham ([@CR93]) have recently reviewed 77 published reports that examine the ability of haematopoietic cells to generate hepatocytes in the liver. They conclude that haematopoietic cells do not trans-differentiate into hepatocytes and contribute little to hepatocyte formation under physiological or pathological conditions. Although fusion clearly is the only established way to generate hepatocytes from blood stem cells so far, the debate concerning whether this is the only mechanism has not yet been decided (Thorgeirsson and Grisham [@CR93]).

In contradiction to these findings, other groups report bone-marrow-derived liver cells without fusion of haematopoietic donor and host liver cells. In a sophisticated study with the Cre/lox recombinase system, Harris et al. ([@CR31]) have shown that bone-marrow-derived epithelial cells occur in the liver, lung, and skin without cell fusion. Whether these cells develop by the transdifferentiation of haematopoietic stem cells or by the differentiation of multipotent epithelial precursors existing in the bone marrow preparation remains to be investigated. The derivation of multipotent adult progenitor cells during the culture of bone marrow cells has been well examined by the group of C. Verfaillie (Reyes et al. [@CR71]) and the feasibility of in vivo (Schwartz et al. [@CR77]) and in vitro (Jiang et al. [@CR41]) differentiation into hepatocytes has been demonstrated. However, the data remain preliminary and functional analyses in terms of transplantation experiments have not yet been performed.

Another group has studied the conversion of haematopoietic stem cells into liver cells in vitro by using a co-culture system in which the stem cells are separated from a CCl~4~-damaged liver section (Jang et al. [@CR40]). The authors again conclude that microenvironmental cues rather than fusion are responsible for the germ layer switching of the haematopoietic stem cells. Moreover, highly enriched male haematopoietic stem cells were injected, via the tail vein, into irradiated female mice in vivo. A subgroup of mice received CCl~4~ additionally to increase liver injury. Confocal serial imaging showed mostly diploid (XY) or tetraploid (XXYY) male cells expressing hepatic marker proteins such as albumin and only a few cells with a fusion-related karyotype (XXXY). Aurich et al. ([@CR6]) have reported that human bone-marrow-derived mesenchymal stem cells can be pre-differentiated towards a hepatic phenotype in vitro, before transplantation into RAG2-mice. The authors have demonstrated the presence of single human hepatocyte-like cells with no signs of fusion in this experimental setting (Aurich et al. [@CR6]).

Different explanations can be presented for these contradictory results. First, the chronic damage in the FAH^-/-^ mice causes chromosomal instability (Jorquera and Tanguay [@CR43]) that may facilitate fusion events. Second, the type and extent of liver damage (metabolic disorders, irradiation, toxic injury, ischaemia) may play a role. Third, it may be important to transplant very early haematopoietic progenitors in a sufficient number to see conversion into epithelial cells.

These hypotheses may also explain the failure of other groups to show a significant impact of bone-marrow-derived cells on liver regeneration in mice (Cantz et al. [@CR12]; Kanazawa and Verma [@CR45]; Wagers et al. [@CR100]). Although the age of donor mice, the severity of liver damage between different mouse strains (Shi et al. [@CR79]) and the experimental settings are not similar in these published experiments, they clearly show that the use of bone-marrow-derived cells for the treatment of liver diseases is far from clinical application and that additional basic research on reprogramming is needed.

Human umbilical cord blood {#Sec9}
--------------------------

Some researchers have argued that stem cells derived from bone marrow or cord blood of human origin exhibit higher plasticity than the respective mouse or rat cells (Di Campli et al. [@CR18]; Ishikawa et al. [@CR37]; Kakinuma et al. [@CR44]; Newsome et al. [@CR61]; Tanabe et al. [@CR87]; Turrini et al. [@CR97]; Wang et al. [@CR101]). Indeed, several groups have detected high rates of human hepatocyte formation without signs of fusion in xenogenic murine transplantation models. In 2003, Newsome and his colleagues demonstrated that human umbilical cord-blood (hUCB)-derived cells could differentiate into hepatocytes after transplantation into immunodeficient mice (Newsome et al. [@CR61]). In their study, unsorted mononuclear hUCB cells were transplanted into sub-lethally irradiated NOD/SCID mice and the livers were analysed after 1, 4, 6 and 16 weeks for the presence of human hepatocytes. The percentage of human compared with mouse hepatocytes reached an average of 0.011% after 16 weeks, whereas no additional damage to the host liver was inflicted, other than the sub-lethal irradiation before reconstitution of the bone marrow. The absence of mouse and human DNA together within single cells ruled out fusion as the underlying mechanism for the stem cell plasticity and once again favoured the transdifferentiation theory. From these experiments, the questions arose as to whether the hUCB had an even higher plasticity than bone-marrow-derived stem cells or whether the immunodeficient NOD/SCID mice facilitated the transdifferentiation of transplanted stem cells. To investigate these points, mononuclear bone marrow cells from enhanced-GFP transgenic mice and hUCB cells were transplanted, with the same protocol, into NOD/SCID mice and, in addition, hepatocellular damage with CCl~4~ was administered (Sharma et al. [@CR78]). No donor-derived cells were detectable after transplantation of murine bone marrow cells but some single hepatocytes and even a few clusters of human origin were detected in the hUCB-transplanted mice. However, marker expression was incomplete in these cells. Serial sections of the recipient livers revealed a mixed expression of mouse and human antigens indicating fused "chimerical" mouse/human hepatocytes in the recipient mouse livers (Sharma et al. [@CR78]).

In 2004, human cord-blood-derived multipotent cells were described by Kögler and colleagues( [@CR49]). These "unrestricted somatic stem cells" (USSC) could differentiate into hepatocytes after transplantation into a pre-immune fetal sheep model (Kögler et al. [@CR49]). Subsequently, the fusion of USSC with host hepatocytes was ruled out by using species-specific polymerase chain reaction on micro-dissected tissue samples (G. Kögler, personal communication).

The infusion of particular subsets of haematopoietic stem cells (Liv8^-^) may be of therapeutic benefit, even in the absence of hepatocyte formation. According to one recently published study, haematopoietic stem cells can partially revert CCl~4~-induced fibrosis of the mouse liver through the activation of the matrix metalloproteinase-9 and improves the survival of the animals (Sakaida et al. [@CR73]).

Embryonic stem cells {#Sec10}
--------------------

Embryonic stem (ES) cells can be maintained in a state of pluripotency for long periods of time and can be grown in large numbers (Boiani and Scholer [@CR10]; Keller [@CR47]; Rathjen and Rathjen [@CR70]). Under appropriate culture conditions, ES cells spontaneously form all somatic cell types of the adult body, including endoderm-derived cells and hepatic progenitors. The non-directed differentiation of ES cells can be achieved through the formation of embryoid bodies (EB), which contain cells representing lineages derived from the three germ layers: ectoderm, mesoderm and endoderm. Subsequent inoculation of the EB-derived cells onto adherent matrices facilitates differentiation into hepatocyte-like cells in the presence of a variety of growth factors, cytokines and hormones, such as hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and dexamethasone. Significant progress has been made in identifying factors and developing protocols to enforce the differentiation of ES cells into cells of the hepatocyte lineage (Chinzei et al. [@CR14]; Choi et al. [@CR15]; Gouon-Evans et al. [@CR28]; Hamazaki et al. [@CR30]; Heo et al. [@CR33]; Ishizaka et al. [@CR38]; Jones et al. [@CR42]; Kania et al. [@CR46]; Miyashita et al. [@CR59]; Teratani et al. [@CR89]; Yamada et al. [@CR106]; Yin et al. [@CR107]). Hamazaki and co-workers ([@CR30]) were among the first to generate a high percentage of hepatocyte precursors from murine ES cell cultures in the presence of growth factors. Miyashita et al. ([@CR59]) and Kania et al. ([@CR46]) have subsequently published differentiation protocols that direct the maturation of the primitive ES cells towards cells with a distinct and mature hepatic phenotype and that result in a high percentage of ES hepatic progenitor cells (ES-HPC) in culture. Bone morphogenetic protein-4 has recently been identified as mediating an important signal in the development of cells with a hepatic phenotype from ES cells (Gouon-Evans et al. [@CR28]).

The transplantation of contaminating pluripotent ES cells carries the risk of teratoma formation and may mask or inhibit the formation of hepatocytes and normal liver tissue from ES-HPC. Cell-sorting techniques utilising either antibodies directed against lineage-specific surface markers of the desired cell population or cell-type-specific expression of reporter genes have been established to eliminate contaminating undifferentiated ES cells and thus to reduce the risk of teratoma formation (Klug et al. [@CR48]). Another strategy to prevent teratoma formation is to implant the ES-HPC into devices for bio-artificial liver support (Soto-Gutierrez et al. [@CR83]).

Hepatocyte formation derived from sorted ES-HPC has recently been demonstrated in fumaryl-acetoacetate-deficient (FAH^-/-^) and uroplasminogen-activator transgenic MUP-uPA/SCID mice, clearly indicating the potential of ES-HPC for cellular therapies (Gouon-Evans et al. [@CR28]; Heo et al. [@CR33]). The rate of hepatocyte and liver tissue formation, however, is much lower than that previously reported for transplanted primary adult hepatocytes or fetal hepatoblasts (Fig. [1](#Fig1){ref-type="fig"}). The reduced efficacy of hepatocyte and liver tissue formation may have been attributable to lower primary engraftment rates of the ES-HPC into the recipient liver, incomplete differentiation or a combination of both. Fig. 1Transplantation of ES-derived hepatic progenitor cells. Embryonic stem cells can be differentiated towards a hepatic progenitor cell-phenotype (ES-HPC). After transplantation of wild-type ES-HPCs into immunosuppressed FAH^-/-^ mice, engraftment of single cells (*arrowheads*) and formation of regeneration nodules after ES-HPC proliferation (*arrows*) can be observed. The 3-amino-9-ethylcarbazole-substrate staining of the cells demonstrates the presence of FAH-enzyme activity in the FAH^-/-^ recipient liver. *Bar* 25 μm

Future directions {#Sec11}
=================

The transplantation of mature hepatocytes into humans over the past 20 years has provided insights regarding the way in which to treat human liver disease by cellular therapies. The shortage of adult hepatocytes from donated organs has given a strong impetus to the search for alternative cellular resources. Stem-cell-based therapies for the liver, however, have not yet reached the stage of clinical application. Progenitor cell lines derived from normal human liver tissue may be an alternative source of hepatocytes for therapy in the future, although isolation, cultivation and propagation protocols will have to be improved substantially. Human fetal liver progenitor cells have been shown to engraft and proliferate in rodents and could eventually become an important source for liver cell therapy, if fetal liver cells can be successfully expanded in vitro. Currently, transplantation into FAH^-/-^ mice is the only model in which haematopoietic cells have contributed to liver repopulation to a degree relevant for clinical application. The underlying mechanism is fusion with host hepatocytes, providing an additive gene transfer, which rescues the metabolic defect. However, the frequency of in vivo fusion of macrophages and endogenous hepatocytes is below the requirements of most clinical applications, which lack a selection pressure as strong as that in the FAH^-/-^ model.

The application of stem cells in liver therapies seems to be a promising approach for the treatment of liver diseases. However, several issues still have to be addressed to fulfil this promise. We need to identify, both inside and outside of the liver, the stem cell candidates that are able to form hepatocytes in vitro and functional liver tissue after transplantation in vivo. The fundamental molecular pathways involved in the differentiation of hepatocytes and cholangiocytes from stem/progenitor cells, the factors that are responsible for in vitro differentiation of various stem cells into hepatocytes, the mechanisms involved in the fusion of macrophages and hepatocytes and the aspects that can potentially enhance these mechanisms need to be studied in more detail. Finally, the role of hepatic stem/progenitor cells in response to liver injury and in the normal regeneration of liver must be elucidated further. With future progress in research into stem cell biology, hepatic stem/progenitor cells, embryonic and adult extrahepatic stem cells should provide great potential for the treatment of liver disorders.

Fig. 2Stem cells in liver regeneration and therapy. Under physiological conditions, the division and proliferation of mature hepatocytes maintain hepatocyte number, i.e. liver mass. In humans and rodents, a 75% partial hepatectomy can be regenerated by this capacity. Under experimental conditions or carcinogenic changes, hepatocyte proliferation can be blocked. In this case, resident hepatic stem/progenitor cells (*rHSPC*) proliferate and differentiate into hepatocytes. The recent literature suggests the existence of an extra-hepatic stem cell pool that contributes to liver regeneration. Bone-marrow-cell-derived cells, e.g. mesenchymal stem cells, can give rise to hepatocytes in distinct experimental settings. Cell transplantation of adult and fetal hepatocytes has been established at the stage of phase-I clinical trials in patients with metabolic liver disorders or acute liver failure. Embryonic-stem-cell-derived hepatic cells are currently being investigated as a transplantable cell source in order to overcome limitations in cell number and tissue compatibility for future therapeutic strategies
